This method could usher in a new approach to delivery of drugs in general
Freiburg researchers find purely chemical way to target therapeutic nano-containers to cells
Scientists have discovered that a polymer can provide a key to get into tumors: Prof. Prasad Shastri, Director of the Institute of Macromolecular Chemistry and core member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg, and graduate students Julia Voigt and Jon Christensen have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells. Using just charged polymers with the right affinity for cell lipids the team has developed nanoparticles that can recognize specific cell types simply by their chemical properties. “This is a remarkable discovery, as it allows for the first time to target a specific cell type purely through biophysical principles, and without using the traditional ligand-receptor approach” says Prof. Shastri who led the study that was selected as cover article of the Proceedings of the National Academy of Sciences. Until now researchers placed molecules on nanoparticles that can latch onto proteins on cell surface – called receptors.
These receptors act as an address or a biological postal code. However in tumors these addresses can change rapidly with time. To solve this lack of precision Shastri and team developed particles that are delivered to endothelial cells using a biophysical approach. “This delivery approach does not require a biological postal code for targeting of nanoparticles and is an important step forward in developing nanoparticle based systems for treating cancers” says Julia Voigt the lead author of the paper.
Cancers are very hungry tissues and they need constant nourishment. This is provided through their own supply of blood vessels. “By going after endothelial cells that make up these blood vessels, we can starve the tumor or kill it with one payload” says Jon Christensen who is a co-author on this study and works on tumor metastasis.
Nanoparticles are used to deliver therapeutics in treating cancers. These very small pills, cornerstones of nanomedicine, get injected into the body and reach the tumor cells via the bloodstream. When they find the targeted cells, they need to be eaten so that the drug can act within the cell.
The Latest on: Nanomedicine
via Google News
The Latest on: Nanomedicine
- Bankrupt biopharmas are rare. 2019 has some worried that’s changing.on November 20, 2019 at 8:02 am
Company executives believed its nanomedicine platform, while only through Phase 1 tests, represented the next advance in cancer therapies. Those dreams came undone within three years. As its ...
- Healthcare Nanotechnology (Nanomedicine) Market Share, Emerging Trends and Forecasts To 2022on November 20, 2019 at 3:54 am
Nov 20, 2019 (AmericaNewsHour) -- The term Nanotechnology is used when the developments occur at very miniscule 0.1 to 100 nm scale. Nanomedicine is an offshoot of Nanotechnology which basically ...
- Nanomedicine Market : Global Market Opportunities, Size, Share, Emerging Trends, Technological Innovation And Forecasts To 2023on November 19, 2019 at 10:10 pm
Nov 20, 2019 (AmericaNewsHour) -- Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing ...
- Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025on November 7, 2019 at 5:35 am
Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025 PR Newswire PALM BEACH, Florida, Nov. 7, 2019 Financialnewsmedia.com News Commentary PALM BEACH, Florida, Nov.
- Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollarson October 29, 2019 at 8:03 am
PALM BEACH, Florida, Oct. 29, 2019 /PRNewswire/ -- There is much activity in the nanotechnology & nanomedicine markets as new treatments and human clinical trials are growing at a record pace. And ...
- Week In Review: Suzhou's Ascentage Pharma Stages $53 Million IPO In Hong Kongon October 27, 2019 at 5:19 am
Taiwan Liposome Company completed a $27.3 million secondary offering to advance its nanomedicine candidates for pain management, ophthalmology and oncology. Milu Labs, a Philadelphia company focused ...
- Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8on October 23, 2019 at 5:00 pm
SALT LAKE CITY, Oct. 24, 2019 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of new preclinical neuroprotection data in multiple ...
- TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicineon October 21, 2019 at 2:38 am
In addition, in vivo findings in which TLC590 showed no dose-related toxicity and other preclinical data were recently published in the International Journal of Nanomedicine. TLC590 is a non-opioid, ...
- A Nanomedicine Technology Sampler Packon October 1, 2019 at 4:10 am
Instead of gorging at a full nanomedicine buffet, try nibbling on a few apps to get a taste for small things with big impacts Nanomedicine options are expanding so quickly that staying up to date can ...
- Novel anti-cancer nanomedicine for efficient chemotherapyon September 17, 2019 at 7:54 am
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy. This new nano-tool provides a new approach to use cell-based nanomedicines for efficient cancer chemotherapy ...
via Bing News